Nav: Home

Prevalence of hepatitis C rates in Ohio may indicate highest areas of opioid misuse

November 07, 2019

In an effort to further measure the opioid epidemic's impact in Ohio, the Ohio Alliance for Innovation in Population Health (The Alliance) studied hepatitis C rates within the state and discovered consistently high rates in the southern Appalachia region over a five-year period.

According to Orman Hall, a research team member on the study and executive in residence at Ohio University's College of Health Sciences and Professions (CHSP), these findings support the notion that Appalachian Ohio has been the hardest hit area of the state's opioid epidemic. Dr. Rifat Haider, assistant professor in CHSP's Department of Social and Public Health, concurred.

"Hepatitis C is growing in incidence in southeast Ohio and it is directly linked to injectable drug use and injectable drug use is directly linked to opioid misuse," he said.

Research conducted by Haider showed national trends in injectable heroin use increased from 2015 to 2017. This increase created a rising trend in hepatitis incidences as well.

Hepatitis C is a blood-borne virus that infects the liver and is spread most commonly by sharing needles. Although curable, most who are infected suffer long-term health problems if left untreated and there is no vaccine for hepatitis C.

The Alliance's study focused on statistics from the Hepatitis Surveillance Program -- a service of the Ohio Department of Health -- from 2014 through 2018. Over those five years, 84,637 cases of hepatitis C were recorded in Ohio. After 12,012 cases were reported in 2014, and an increase to 15,581 cases in 2015, the number of hepatitis C incidents peaked in 2016 at 20,866 before dropping to 19,432 in 2017 and further decreased to 16,746 in 2018.

"Significant attention has been drawn to the severity of opioid overdose deaths within Ohio's Appalachian counties and overdose deaths are an important measure of the impact of the opioid epidemic in our state. However, it is important to note that overdose death rates can be influenced by a wide range of factors," Hall said. "Hepatitis C is often linked to intravenous drug use as one of the major sources of infection is the practice of sharing used (and potentially infected) needles. These findings illustrate the reported incidents of hepatitis C and suggests the prevalence of opioid misuse in various areas of the state."

According to the study, five southern Appalachia counties exhibited the highest five-year average hepatitis C rates per 100,000 population in the state, including:
  • Pike -- 522
  • Scioto -- 430
  • Gallia -- 386
  • Lawrence -- 370
  • Meigs -- 314
Meanwhile, the counties of Putnam (30), Holmes (32), Delaware (52), Auglaize (52) and Geauga (57) had the lowest five-year average rates per 100,000 population.

Southern Appalachia had the highest average rates with northern Appalachia landing just below metropolitan areas for second highest reported incidents. In terms of age, those between 20-29 exhibited the highest hepatitis C rates, followed by 30-39 and 50-59 which had slightly higher rates than the 40-49 age bracket. Few incidents were recorded for persons under the age of 19.

Haider said he hopes the study will shine a light on the need for screenings for those at high-risk for the disease and that more physicians -- especially in areas of high opioid incidence -- should be provided the opportunity to present screening as an option for patients.

Dr. Sebastian Diaz, associate professor in the Heritage College of Osteopathic Medicine, added, "The data from this study promotes holistic perspectives of community health by highlighting interrelationships among hepatitis C and opioid use disorder rates. The Alliance's work in this regard is crucial toward providing community health stakeholders with these invaluable perspectives."

A full report of the statistics from the study -- including a county-by-county breakdown -- is available online. Previous studies conducted by The Alliance are also available.

Ohio University

Related Hepatitis Articles:

Hepatitis B: New therapeutic approach may help to cure chronic hepatitis B infection
Researchers at Helmholtz Zentrum München, Technical University of Munich (TUM) and the German Center for Infection Research (DZIF) have developed a novel therapeutic approach to cure chronic hepatitis B.
Anti-hepatitis medicine surprises
A new effective treatment of hepatitis C not only combats the virus, but is also effective against potentially fatal complications such as reduced liver functioning and cirrhosis.
Nanotechnology delivers hepatitis B vaccine
X-ray imaging shows that nanostructured silica acts as a protective vehicle to deliver intact antigen to the intestine so that it can trigger an immune response.
Checkmate for hepatitis B viruses in the liver
Researchers at Helmholtz Zentrum München and the Technical University of Munich, working in collaboration with researchers at the University Medical Center Hamburg-Eppendorf and the University Hospital Heidelberg, have for the first time succeeded in conquering a chronic infection with the hepatitis B virus in a mouse model.
How common is Hepatitis C infection in each US state?
Hepatitis C virus infection is a major cause of illness and death in the United States and injection drug use is likely fueling many new cases.
New strains of hepatitis C found in Africa
The largest population study of hepatitis C in Africa has found three new strains of the virus circulating in the general population in sub-Saharan Africa.
High stability of the hepatitis B virus
At room temperature, hepatitis B viruses (HBV) remain contagious for several weeks and they are even able to withstand temperatures of four degrees centigrade over the span of nine months.
Findings could lead to treatment of hepatitis B
Researchers have gained new insights into the virus that causes hepatitis B -- a life-threatening and incurable infection that afflicts more than 250 million people worldwide.
How to cure more hepatitis C patients
The cost of cures for hepatitis C have been prohibitive, but experts who served on an NAS panel have a solution that will save more patients and incentivize drug innovation.
Hepatitis C: A novel point-of-care assay
One of the major challenges identified by the WHO in efforts to eradicate the hepatitis C virus is the diagnosis of chronic cases that are generally asymptomatic.
More Hepatitis News and Hepatitis Current Events

Trending Science News

Current Coronavirus (COVID-19) News

Top Science Podcasts

We have hand picked the top science podcasts of 2020.
Now Playing: TED Radio Hour

Teaching For Better Humans 2.0
More than test scores or good grades–what do kids need for the future? This hour, TED speakers explore how to help children grow into better humans, both during and after this time of crisis. Guests include educators Richard Culatta and Liz Kleinrock, psychologist Thomas Curran, and writer Jacqueline Woodson.
Now Playing: Science for the People

#556 The Power of Friendship
It's 2020 and times are tough. Maybe some of us are learning about social distancing the hard way. Maybe we just are all a little anxious. No matter what, we could probably use a friend. But what is a friend, exactly? And why do we need them so much? This week host Bethany Brookshire speaks with Lydia Denworth, author of the new book "Friendship: The Evolution, Biology, and Extraordinary Power of Life's Fundamental Bond". This episode is hosted by Bethany Brookshire, science writer from Science News.
Now Playing: Radiolab

One of the most consistent questions we get at the show is from parents who want to know which episodes are kid-friendly and which aren't. So today, we're releasing a separate feed, Radiolab for Kids. To kick it off, we're rerunning an all-time favorite episode: Space. In the 60's, space exploration was an American obsession. This hour, we chart the path from romance to increasing cynicism. We begin with Ann Druyan, widow of Carl Sagan, with a story about the Voyager expedition, true love, and a golden record that travels through space. And astrophysicist Neil de Grasse Tyson explains the Coepernican Principle, and just how insignificant we are. Support Radiolab today at